...
机译:2型糖尿病和磺酰脲类的心血管成果试验:活性比较Carolina试验的理由
Dallas Diabetes and Endocrine Center at Medical City Dallas TX United States;
Department of Internal Medicine i University Hospital Aachen Pauwelsstra?e 30 52074 Aachen;
Division of Metabolism Endocrinology and Nutrition Department of Medicine VA Puget Sound Health;
Samuel Lunenfeld Research Institute Mount Sinai Hospital Toronto ON Canada Division of;
Department of Vascular Medicine Academic Medical Center Amsterdam Netherlands;
Biostatistics Center George Washington University Rockville MD United States;
Boehringer Ingelheim Biberach Germany;
Boehringer Ingelheim Bracknell United Kingdom;
Boehringer Ingelheim Ingelheim Germany;
Boehringer Ingelheim Ingelheim Germany;
cardiovascular disease; dipeptidyl peptidase-4 inhibitor; oral glucose-lowering agent; sulphonylurea; Type 2 diabetes mellitus;
机译:2型糖尿病和磺酰脲类的心血管成果试验:活性比较Carolina试验的理由
机译:随机,设计和组织在2型糖尿病患者中与SitaGliptin(TECOS)评估心血管结果的随机,对照试验评估心血管结果,并建立心血管疾病
机译:CAROLINA的原理和设计? -认知亚研究:利格列汀与格列美脲对2型糖尿病患者认知结局的随机对照试验
机译:Romeo(重新思考组织改善教育和结果)的基本理由,设计和初步结果,在1型糖尿病的术语中进行了随机对照的组织的多中心试验
机译:运动训练强度对2型糖尿病患者身体素质和身体功能的影响:一项随机临床试验。
机译:CAROLINA®的概念和设计-认知子研究:利格列汀与格列美脲对2型糖尿病患者认知结局的随机对照试验
机译:2型糖尿病和磺脲类药物争议的心血管预后试验:主动比较药CAROLINA试验的理由